DIA
Drug Information Association Logo

Cost-Effectiveness Analysis of EGFR Mutation Testing and Gefitinib as First-Line Therapy for Non Small Cell Lung Cancer

Time

Mon, Jun 16 7:45AM
M 14

Title

Cost-Effectiveness Analysis of EGFR Mutation Testing and Gefitinib as First-Line Therapy for Non Small Cell Lung Cancer

Abstract Summary

A Markov model was used to predict expected costs and outcomes. We included direct medical costs from the healthcare payer’s perspective. Outcomes were based on those reported in IPASS study. Quality-adjusted life-years gained was used to calculate the incremental cost-effectiveness ratio (ICER).

Poster Presenter

Yusuke Narita
Student,
Keio University
Japan